Login / Signup

Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.

Sarah C ZimmermannBridget DuvallTakashi Tsukamoto
Published in: Journal of medicinal chemistry (2018)
Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate. GLS was found to be upregulated in many glutamine-dependent cancer cells. Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metabolism. Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochemical properties, has served as a key molecular template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors. This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into "druglike" compounds guided by systematic SAR studies.
Keyphrases
  • small molecule
  • ionic liquid
  • papillary thyroid
  • squamous cell carcinoma
  • high throughput
  • mass spectrometry
  • quality improvement
  • squamous cell
  • anti inflammatory
  • drug induced
  • childhood cancer